Education
About Us
Working with TipRanks
Follow Us
Genfit SA (GNFT)
OTHER OTC:GNFT
GNFT Analyst Ratings
Moderate Buy
2 Buy
0 Hold
0 Sell
TipRanks enables you to focus on the analyst rating consensus of all analysts or only the top performers in the past 3 months
GNFT Stock 12 Month Forecast
Average Price Target
$7.50
▲(38.38% Upside)
| Highest Price Target$8.00 | Average Price Target$7.50 | Lowest Price Target$7.00 |
The highest, average, and lowest price target of all analysts. Click on ‘Top Analysts’ to focus on the best performers.
Detailed List of Analyst Forecasts
Detailed List of Analyst Forecasts
H.C. Wainwright
$9→$7
Buy
29.15%
Upside
Reiterated
09/24/25
Leerink Partners
$8
Buy
47.60%
Upside
Reiterated
09/23/25
Westpark Capital
$13
Buy
139.85%
Upside
Reiterated
02/07/25
Genfit SA's Promising Clinical Milestones and Financial Stability Underpin Buy RatingFrom ACLF The final Phase 1b dataset from a Phase 1b/2a study of GNS561 in CCA is also expected in 2025. Yesterday, GENFIT announced a list of its 2025 milestones that includes up to four clinical data readouts from its Acute on- Chronic Liver Failure (ACLF) programs. Recall, ACLF is a syndrome defined as the presentation of an acute liver injury in patients with different forms of chronic liver diseases, causing liver and extrahepatic organ failure. It has been estimated that about 137,000 ACLF patients are hospitalized annually in the 28-day mortality rate ranging from 23% to 74%.
Analyst Type
Any
Ranks
Any
Analyst Rating
Any
Upside/ Downside
Any
Action
Any
H.C. Wainwright
$9→$7
Buy
29.15%
Upside
Reiterated
09/24/25
Leerink Partners
$8
Buy
47.60%
Upside
Reiterated
09/23/25
Westpark Capital
$13
Buy
139.85%
Upside
Reiterated
02/07/25
Genfit SA's Promising Clinical Milestones and Financial Stability Underpin Buy RatingFrom ACLF The final Phase 1b dataset from a Phase 1b/2a study of GNS561 in CCA is also expected in 2025. Yesterday, GENFIT announced a list of its 2025 milestones that includes up to four clinical data readouts from its Acute on- Chronic Liver Failure (ACLF) programs. Recall, ACLF is a syndrome defined as the presentation of an acute liver injury in patients with different forms of chronic liver diseases, causing liver and extrahepatic organ failure. It has been estimated that about 137,000 ACLF patients are hospitalized annually in the 28-day mortality rate ranging from 23% to 74%.
Best Analysts Covering Genfit SA
1 Month
xxx
Success Rate
7/12 ratings generated profit
Average Return
+2.07%
reiterated a xxx
rating 3 months ago
Copying xxxxxxxxxxxxxxxxxx
trades and holding each position for 1 Month would result in 58.33% of your transactions generating a profit, with an average return of +2.07% per trade.
3 Months
xxx
Success Rate
7/12 ratings generated profit
Average Return
+1.91%
reiterated a xxx
rating 3 months ago
Copying xxxxxxxxxxxxxxxxxx
trades and holding each position for 3 Months would result in 58.33% of your transactions generating a profit, with an average return of +1.91% per trade.
1 Year
Success Rate
7/12 ratings generated profit
Average Return
+8.59%
reiterated a buy rating 3 months ago
Copying Thomas Smith's trades and holding each position for 1 Year would result in 58.33% of your transactions generating a profit, with an average return of +8.59% per trade.
2 Years
xxx
Success Rate
10/12 ratings generated profit
Average Return
+25.98%
reiterated a xxx
rating 3 months ago
Copying xxxxxxxxxxxxxxxxxx
trades and holding each position for 2 Years would result in 83.33% of your transactions generating a profit, with an average return of +25.98% per trade.
The Best Analyst Covering tool allows you to follow the analysts who have the best success rates and average returns on a specific stock. Only analysts that gave a Buy or Sell rating on the stock in the past 12 months are eligible for inclusion in this tool. Follow the analysts of your choice to receive real-time updates when they publish a new rating.
GNFT Analyst Recommendation Trends
Rating
Aug 25
Sep 25
Oct 25
Nov 25
Dec 25
Strong Buy
1
3
3
2
0
Buy
0
0
0
0
0
Hold
6
8
9
8
6
Sell
0
0
0
0
0
Strong Sell
0
0
0
0
0
total
7
11
12
10
6
Each month's total comprises the sum of three months' worth of ratings.
GNFT Financial Forecast
GNFT Stock Forecast FAQ
What is GNFT’s average 12-month price target, according to analysts?
Based on analyst ratings, Genfit SA’s 12-month average price target is 7.50.
What is GNFT’s upside potential, based on the analysts’ average price target?
Genfit SA has 38.38% upside potential, based on the analysts’ average price target.
Can I see which stocks the top-ranking analysts are rating?
Yes, go to the Analysts’ Top Stocks tool to see stocks with a Strong Buy or Strong Sell analyst rating consensus, according to the top performers.
How can I follow the stock ratings of top Wall Street analysts?
Head over to our Expert Center to see a list of the top 100 Wall Street analysts and follow the analysts of your choice. Visit their profiles for more details about their stock ratings and see how they perform on a stock-by-stock basis.
Is GNFT a Buy, Sell or Hold?
Genfit SA has a consensus rating of Moderate Buy which is based on 2 buy ratings, 0 hold ratings and 0 sell ratings.
What is Genfit SA’s price target?
The average price target for Genfit SA is 7.50. This is based on 2 Wall Streets Analysts 12-month price targets, issued in the past 3 months.
The highest analyst price target is $8.00 ,the lowest forecast is $7.00. The average price target represents 38.38% Increase from the current price of $5.42.
The highest analyst price target is $8.00 ,the lowest forecast is $7.00. The average price target represents 38.38% Increase from the current price of $5.42.
What do analysts say about Genfit SA?
Genfit SA’s analyst rating consensus is a Moderate Buy. This is based on the ratings of 2 Wall Streets Analysts.
How can I buy shares of GNFT?
Open a brokerage account, see exclusive account opening deals on our Best Online Brokers page.